EquityZen Growth Technology Fund LLC - Series 2131
Raised
$723K
Investors
20
Min Invest
$1,005
AltStreet Analysis
·Generated from EDGAR primary sources
EquityZen Growth Technology Fund LLC - Series 2131 is a Delaware pooled investment fund vehicle filed by EquityZen Advisors LLC, raising $723K from 20 investors under Rule 506(b) and Section 3(c)(1) exemptions with a $1K minimum investment. This is part of EquityZen's pre-IPO access platform, which operates over 1,800 series vehicles enabling secondary market transactions in private company shares.
This pre-IPO fund follows the standard EquityZen template: 506(b) / 3(c)(1) exemptions with sub-$1M raises and accessible minimums ($1K). The low barrier to entry and pooled structure are consistent with retail-accessible pre-IPO exposure, typical of secondary market enablement vehicles in the growth technology sector.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
EquityZen Advisors LLC
Executive Officer, Director · New York, NY
Phil Haslett
Executive Officer, Director · New York, NY
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
